LAW

R.I. to receive $1.2M from suit with GlaxoSmithKline

BLOOMBERG FILE PHOTO/JB REED
RHODE ISLAND will receive $1.24 million as part of a lawsuit against GlaxoSmithKline for deceptive marking techniques of the company's Avandia drug.
Posted 11/15/12

PROVIDENCE – Rhode Island is set to receive $1.24 million as part of a lawsuit against GlaxoSmithKline LLC over deceptive marketing practices concerning the diabetes drug Avandia, R.I. Attorney General Peter F. Kilmartin announced Thursday.

Rhode Island’s $1.2 million is part of a $90 million consent judgement in a case between the company and 38 states to resolve allegations that GlaxoSmithKline unlawfully promoted Avandia.

It was alleged that the company engaged in “unfair and deceptive practices” during its advertising by misrepresenting Avandia’s cardiovascular risks and safety profile.

“Time and time again, pharmaceutical companies ignore consumer protection laws, make claims not supported by clinical experience, and misrepresent information, all in the name of racking up steep profits,” Kilmartin said in a statement.

As part of the consent judgment, GlaxoSmithKline agreed to reform how it markets and promotes Avandia. Under the settlement, the company may not: make false, misleading or deceptive claims about any diabetes drug, make comparative safety claims unsupported by evidence or clinical experience, present invalid information, promote investigational drugs or misuse statistics to misrepresent the nature, applicability or significant of clinical trial.

Under the consent judgement, the company must adhere to the following terms for at least eight years:

  • GSK must post summaries of all GSK-sponsored observational studies or meta-analyses conducted by GSK that are designed to inform the effective, safe, and/or appropriate use of its diabetes drugs;

  • GSK shall post summaries of GSK-sponsored clinical trials of diabetes products within eight months of the primary completion date;

  • GSK shall register and post all GSK-sponsored clinical trials as required by federal law; and

  • GSK shall comply with the ICMJE Uniform Requirements for Manuscripts submitted to Biomedical Journals.

Calendar
PBN Hosted
Events

Join PBN and two panels of successful female executives, business owners and entrepreneurs as we delve into what women should do to advance their careers, and become leaders in the corporate world and their own enterprises.
  • Book of Lists Party
    Save the date - January 15, 2015 for PBN's Book of Lists Party at the Providence ...
  • Best Places to Work
    Enrollment is now open for the 7th annual Best Places to Work program. Winners w ...
Advertisement
Purchase Data
Book of Lists
Lists
Book of Lists cover
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.
Data icons
Data can be purchased as single lists, in either Excel or PDF format; the entire database of the published book, in Excel format; or a printed copy of the Book of Lists.
  • Purchase an e-File of a single list
  •  
  • Purchase an e-File of the entire Book of Lists database
  •  
  • Purchase a printed copy of the Book of Lists
  •  
    National
    Local
    Latest News
    Advertisement